In vitro studies on gemcitabine combinations with other antiblastics

Annals of Oncology

Volumn 17, Issue SUPPL. 5, 2006, Pages

  Giovannetti, E ^a   Danesi, R ^a   Mey, V ^a   Nannizzi, S ^a   Pasqualetti, G ^a   Del Tacca, M ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Drug interaction; Gemcitabine; Metabolism

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; CARBOPLATIN; CELL DNA; CISPLATIN; DOXORUBICIN; FLUOROPYRIMIDINE DERIVATIVE; FOLIC ACID ANTAGONIST; GAMMA INTERFERON; GEMCITABINE; NAVELBINE; NUCLEOSIDE ANALOG; NUCLEOTIDE; PACLITAXEL; PEMETREXED; PROTEIN KINASE B; RAPAMYCIN; TAXANE DERIVATIVE; TOPOTECAN; VINBLASTINE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; DNA REPAIR; DNA SYNTHESIS INHIBITION; DRUG ANTAGONISM; DRUG BINDING SITE; DRUG METABOLISM; DRUG POTENTIATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DRUG EVALUATION, PRECLINICAL; DRUG INTERACTIONS; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; PRODRUGS; TUMOR CELLS, CULTURED;

EID: 33745596430     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdj943     Document Type: Article

References (16)

1. Mackey JR, Jennings LL, Clarke ML et al. Immunohistochemical variation of human equilibrative nucleoside transporter 1 protein in primary breast cancers. Clin Cancer Res 2002; 8: 110-116.
2. Blackstock AW, Lightfoot H, Case LD et al. Tumor uptake and elimination of 2′,2′-difluoro-2′-deoxycytidine (gemcitabine) after deoxycytidine kinase gene transfer: Correlation with in vivo tumor response. Clin Cancer Res 2001; 7: 3263-3268.
3. Lotfi K, Mansson E, Chandra J et al. Pharmacological basis for cladribine resistance in a human acute T lymphoblastic leukaemia cell line selected for resistance to etoposide. Br J Haematol 2001; 113: 339-346.
4. Eda H, Ura M, K FO et al. The antiproliferative activity of DMDC is modulated by inhibition of cytidine deaminase. Cancer Res 1998; 58: 1165-1169.
5. Davidson JD, Ma L, Flagella M et al. An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines. Cancer Res 2004; 64: 3761-3766.
6. Goan YG, Zhou B, Hu E et al. Overexpression of ribonucleotide reductase as a mechanism of resistance to 2,2-difluorodeoxycytidine in the human KB cancer cell line. Cancer Res 1999; 59: 4204-4207.
7. Giovannetti E, Mey V, Danesi R et al. Synergistic cytotoxicity and pharmacogenetics of gemcitabine and pemetrexed combination in pancreatic cancer cell lines. Clin Cancer Res 2004; 10: 2936-2943.
8. Giovannetti E, Mey V, Danesi R et al. Interaction between gemcitabine and topotecan in human non-small-cell lung cancer cells: Effects on cell survival, cell cycle and pharmacogenetic profile. Br J Cancer 2005; 92: 681-689.
9. Giovannetti E, Mey V, Nannizzi S et al. Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells. Mol Pharmacol 2005; 68: 110-118.
10. Konecny G, Untch M, Slamon D et al. Drug interactions and cytotoxic effects of paclitaxel in combination with carboplatin, epirubicin, gemcitabine or vinorelbine in breast cancer cell lines and tumor samples. Breast Cancer Res Treat 2001; 67: 223-233.
11. Mondesire WH, Jian W, Zhang H et al. Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells. Clin Cancer Res 2004; 10: 7031-7042.
12. Perabo FG, Lindner H, Schmidt D et al. Preclinical evaluation of gemcitabine/paclitaxel-interactions in human bladder cancer lines. Anticancer Res 2003; 23: 4805-4814.
13. Rohde D, Hayn HK, Blatter J, Jakse G. The efficacy of 2′,2′ -difluorodeoxycytidine (gemcitabine) combined with interferon in human renal cell carcinoma cell lines. Int J Oncol 1998; 12: 1361-1366.
14. Smith JA, Brown J, Martin MC et al. An in vitro study of the inhibitory activity of gemcitabine and platinum agents in human endometrial carcinoma cell lines. Gynecol Oncol 2004; 92: 314-319.
15. Yang LY, Li L, Jiang H et al. Expression of ERCC1 antisense RNA abrogates gemicitabine-mediated cytotoxic synergism with cisplatin in human colon tumor cells defective in mismatch repair but proficient in nucleotide excision repair. Clin Cancer Res 2000; 6: 773-781.
16. Zhang M, Boyer M, Rivory L et al. Radiosensitization of vinorelbine and gemcitabine in NCI-H460 non-small-cell lung cancer cells. Int J Radiat Oncol Biol Phys 2004; 58: 353-360.